Effectiveness of Madopar HBS plus Madopar standard in patients with fluctuating Parkinson's disease

Two years of follow-up

C. Pacchetti, E. Martignoni, L. Sibilla, P. Bruggi, M. Turla, G. Nappi

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Clinical response to a new galenic formulation of levodopa plus benserazide, Madopar HBS, was studied in 25 fluctuating parkinsonians. This open study was planned in two phases. In the first phase, the administering of HBS alone resulted in a surprisingly high number of dropouts. In the second phase, Madopar standard in association with Madopar HBS, the follow-up period was 24 months. A stable long-lasting improvement in predictable fluctuations and their severity was maintained for the whole period without any change in drug dose. Nocturnal and early morning akinesia improved too. The study shows that Madopar HBS plus Madopar standard is effective in producing a prolonged and stable response in parkinsonian fluctuating patients.

Original languageEnglish
Pages (from-to)319-323
Number of pages5
JournalEuropean Neurology
Volume30
Issue number6
Publication statusPublished - 1990

Fingerprint

Parkinson Disease
levodopa drug combination benserazide
Pharmaceutical Preparations

Keywords

  • long-term study
  • Madopar HBS
  • motor fluctuations
  • Parkinson's disease

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Effectiveness of Madopar HBS plus Madopar standard in patients with fluctuating Parkinson's disease : Two years of follow-up. / Pacchetti, C.; Martignoni, E.; Sibilla, L.; Bruggi, P.; Turla, M.; Nappi, G.

In: European Neurology, Vol. 30, No. 6, 1990, p. 319-323.

Research output: Contribution to journalArticle

Pacchetti, C. ; Martignoni, E. ; Sibilla, L. ; Bruggi, P. ; Turla, M. ; Nappi, G. / Effectiveness of Madopar HBS plus Madopar standard in patients with fluctuating Parkinson's disease : Two years of follow-up. In: European Neurology. 1990 ; Vol. 30, No. 6. pp. 319-323.
@article{6ebc98f1fe264f2ca684f31674e997c1,
title = "Effectiveness of Madopar HBS plus Madopar standard in patients with fluctuating Parkinson's disease: Two years of follow-up",
abstract = "Clinical response to a new galenic formulation of levodopa plus benserazide, Madopar HBS, was studied in 25 fluctuating parkinsonians. This open study was planned in two phases. In the first phase, the administering of HBS alone resulted in a surprisingly high number of dropouts. In the second phase, Madopar standard in association with Madopar HBS, the follow-up period was 24 months. A stable long-lasting improvement in predictable fluctuations and their severity was maintained for the whole period without any change in drug dose. Nocturnal and early morning akinesia improved too. The study shows that Madopar HBS plus Madopar standard is effective in producing a prolonged and stable response in parkinsonian fluctuating patients.",
keywords = "long-term study, Madopar HBS, motor fluctuations, Parkinson's disease",
author = "C. Pacchetti and E. Martignoni and L. Sibilla and P. Bruggi and M. Turla and G. Nappi",
year = "1990",
language = "English",
volume = "30",
pages = "319--323",
journal = "European Neurology",
issn = "0014-3022",
publisher = "S. Karger AG",
number = "6",

}

TY - JOUR

T1 - Effectiveness of Madopar HBS plus Madopar standard in patients with fluctuating Parkinson's disease

T2 - Two years of follow-up

AU - Pacchetti, C.

AU - Martignoni, E.

AU - Sibilla, L.

AU - Bruggi, P.

AU - Turla, M.

AU - Nappi, G.

PY - 1990

Y1 - 1990

N2 - Clinical response to a new galenic formulation of levodopa plus benserazide, Madopar HBS, was studied in 25 fluctuating parkinsonians. This open study was planned in two phases. In the first phase, the administering of HBS alone resulted in a surprisingly high number of dropouts. In the second phase, Madopar standard in association with Madopar HBS, the follow-up period was 24 months. A stable long-lasting improvement in predictable fluctuations and their severity was maintained for the whole period without any change in drug dose. Nocturnal and early morning akinesia improved too. The study shows that Madopar HBS plus Madopar standard is effective in producing a prolonged and stable response in parkinsonian fluctuating patients.

AB - Clinical response to a new galenic formulation of levodopa plus benserazide, Madopar HBS, was studied in 25 fluctuating parkinsonians. This open study was planned in two phases. In the first phase, the administering of HBS alone resulted in a surprisingly high number of dropouts. In the second phase, Madopar standard in association with Madopar HBS, the follow-up period was 24 months. A stable long-lasting improvement in predictable fluctuations and their severity was maintained for the whole period without any change in drug dose. Nocturnal and early morning akinesia improved too. The study shows that Madopar HBS plus Madopar standard is effective in producing a prolonged and stable response in parkinsonian fluctuating patients.

KW - long-term study

KW - Madopar HBS

KW - motor fluctuations

KW - Parkinson's disease

UR - http://www.scopus.com/inward/record.url?scp=0025603096&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025603096&partnerID=8YFLogxK

M3 - Article

VL - 30

SP - 319

EP - 323

JO - European Neurology

JF - European Neurology

SN - 0014-3022

IS - 6

ER -